Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 24 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.21 Insider Own3.04% Shs Outstand49.73M Perf Week-13.59%
Market Cap2.30B Forward P/E- EPS next Y-2.64 Insider Trans-7.81% Shs Float48.49M Perf Month-20.60%
Income-59.54M PEG- EPS next Q-0.48 Inst Own79.52% Short Float10.66% Perf Quarter-35.11%
Sales266.18M P/S8.65 EPS this Y-76.91% Inst Trans22.95% Short Ratio10.13 Perf Half Y0.83%
Book/sh7.15 P/B6.44 EPS next Y-32.30% ROA-7.80% Short Interest5.17M Perf Year-20.74%
Cash/sh16.65 P/C2.77 EPS next 5Y- ROE-17.05% 52W Range42.21 - 76.98 Perf YTD-32.60%
Dividend Est.- P/FCF- EPS past 5Y- ROI-7.16% 52W High-40.18% Beta0.83
Dividend TTM- Quick Ratio5.94 Sales past 5Y88.61% Gross Margin99.49% 52W Low9.10% ATR (14)2.61
Dividend Ex-Date- Current Ratio5.96 EPS Y/Y TTM-14.18% Oper. Margin-26.39% RSI (14)18.75 Volatility6.09% 4.53%
Employees497 Debt/Eq1.31 Sales Y/Y TTM33.71% Profit Margin-22.37% Recom1.28 Target Price84.76
Option/ShortYes / Yes LT Debt/Eq1.31 EPS Q/Q-16.29% Payout- Rel Volume9.82 Prev Close47.98
Sales Surprise1.49% EPS Surprise-33.15% Sales Q/Q30.20% EarningsMay 08 BMO Avg Volume510.09K Price46.05
SMA20-18.96% SMA50-21.50% SMA200-21.81% Trades Volume5,006,832 Change-4.02%
Date Action Analyst Rating Change Price Target Change
Apr-29-24Initiated Leerink Partners Outperform $74
Nov-20-23Resumed JP Morgan Overweight $60
Nov-02-23Initiated Cantor Fitzgerald Overweight
Oct-31-23Initiated Robert W. Baird Outperform $84
Sep-13-23Upgrade JP Morgan Neutral → Overweight $9 → $22
Sep-13-23Initiated Needham Buy $75
Aug-16-23Initiated CapitalOne Overweight $84
Jul-17-23Initiated Canaccord Genuity Hold $67
Mar-31-23Initiated Mizuho Buy $70
Mar-30-23Initiated Guggenheim Buy $85
May-24-24 12:00PM
May-08-24 01:54PM
07:15AM Loading…
Apr-29-24 07:15AM
Apr-24-24 10:00AM
Apr-04-24 04:00PM
Mar-13-24 11:07AM
Mar-05-24 04:30PM
Mar-01-24 07:00AM
Feb-29-24 10:51AM
Feb-28-24 04:53PM
Feb-22-24 07:00AM
07:00AM Loading…
Feb-21-24 07:00AM
Feb-01-24 09:00AM
Jan-30-24 11:30PM
Jan-29-24 04:05PM
Jan-10-24 09:55AM
Jan-09-24 01:51PM
Jan-05-24 07:00AM
Jan-03-24 07:00AM
Dec-18-23 12:00PM
Dec-13-23 09:55AM
Nov-30-23 04:00AM
Nov-27-23 09:55AM
Nov-20-23 09:55AM
Nov-14-23 09:09AM
09:55AM Loading…
Nov-10-23 09:55AM
Nov-07-23 07:00AM
Nov-01-23 04:01PM
Oct-30-23 04:30PM
Oct-21-23 08:45AM
Oct-19-23 09:55AM
Oct-07-23 03:33PM
Oct-06-23 07:01AM
Sep-22-23 06:40PM
Sep-14-23 02:02PM
Sep-11-23 05:00PM
Sep-01-23 04:00PM
Aug-13-23 07:15AM
Aug-10-23 10:22PM
Aug-08-23 08:48AM
Aug-03-23 08:00AM
Jul-18-23 06:05AM
Jun-07-23 06:59AM
Jun-03-23 07:00AM
Jun-01-23 04:30PM
May-17-23 01:18AM
May-11-23 06:00AM
May-10-23 07:00AM
May-03-23 04:30PM
Apr-24-23 01:00AM
Apr-19-23 12:00AM
Apr-18-23 07:00AM
Apr-17-23 08:32AM
Apr-11-23 07:00AM
Apr-05-23 06:00PM
Mar-30-23 06:00PM
Mar-28-23 03:57PM
Mar-24-23 06:00PM
Mar-16-23 06:00PM
Mar-14-23 04:30PM
Mar-03-23 10:55AM
Mar-01-23 11:32PM
Feb-28-23 08:30AM
Feb-27-23 01:47PM
Feb-24-23 09:00AM
Feb-23-23 07:00AM
Feb-22-23 05:50PM
Feb-15-23 05:50PM
Feb-14-23 06:57AM
Feb-13-23 05:35PM
Feb-08-23 05:50PM
Feb-03-23 02:58PM
Feb-02-23 05:50PM
Feb-01-23 09:00AM
Jan-30-23 10:20AM
Jan-27-23 05:50PM
Jan-25-23 06:00PM
Jan-20-23 01:34PM
Jan-19-23 06:00PM
Jan-18-23 06:50AM
Jan-13-23 04:41AM
Jan-11-23 08:02AM
Jan-09-23 07:00AM
Jan-06-23 06:35PM
Immunocore Holdings Plc operates as a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX - Immune mobilizing monoclonal TCRs Against X disease. Its lead product KIMMTRAK is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma, in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. The company was founded on January 7, 2021 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
St Leger Tina AmberCHIEF HR OFFICERApr 01 '24Option Exercise29.874,375130,6814,375Apr 03 04:15 PM
St Leger Tina AmberCHIEF HR OFFICERApr 01 '24Sale64.064,375280,2620Apr 03 04:15 PM
Berman David MHEAD OF R&DFeb 28 '24Option Exercise17.4636,509637,44736,509Mar 01 04:15 PM
Berman David MHEAD OF R&DFeb 28 '24Sale68.5936,5092,504,1580Mar 01 04:15 PM
Berman David MHEAD OF R&DFeb 27 '24Option Exercise17.4654,938959,21754,938Feb 28 04:15 PM
Berman David MHEAD OF R&DFeb 27 '24Sale70.8654,9383,893,0300Feb 28 04:15 PM
Berman David MHEAD OF R&DFeb 26 '24Option Exercise17.4628,553498,53528,553Feb 28 04:15 PM
Berman David MHEAD OF R&DFeb 26 '24Sale70.6528,5532,017,2880Feb 28 04:15 PM
St Leger Tina AmberChief HR OfficerJan 03 '24Option Exercise29.874,375130,6814,375Jan 05 04:17 PM
St Leger Tina AmberChief HR OfficerJan 03 '24Sale69.894,375305,7810Jan 05 04:17 PM